company featured image

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well-tolerated, oral treatments of cancer and other serious illnesses.

 

Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.

 

READ MORE

pipeline featured image

Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, pancreatic cancer, breast cancer, and prevention of acute kidney injury in hospitalized patients with pneumonia.

 

READ MORE

doctor viewing vaccine

February 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

 

September 2023 – Cantex Pharmaceuticals and Michigan Medicine announced the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.

 

September 2023 – Cantex Pharmaceuticals and Allegheny Health Network (AHN) announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.

 

 

READ ALL NEWS

CANTEX IS DEVELOPING AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA, BRAIN METASTASES, BREAST CANCER, PANCREATIC CANCER AND PREVENTION OF ACUTE KIDNEY INJURY IN SERIOUSLY ILL PATIENTS.